Summary
GlobalData, the industry analysis specialist's new report, "Acute Heart Failure-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global acute heart failure market. The report identifies the key trends shaping and driving the global acute heart failure market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global acute heart failure sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global acute heart failure market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global acute heart failure market.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with acute heart failure.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global acute heart failure market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acute heart failure market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global acute heart failure market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Acute Heart Failure: Market Characterization 5
2.1 Overview 5
2.2 Acute Heart Failure Market Size 5
2.3 Acute Heart Failure Market Forecast and CAGR 6
2.4 Drivers and Barriers for the AHF Market 8
2.4.1 Drivers of the Acute Heart Failure Market 8
2.4.2 Barriers for the Acute Heart Failure Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Acute Heart Failure Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Acute Heart Failure Market 12
3.3.1 Natrecor (Nesiritide) 12
3.3.2 Primacor (Milrinone Lactate) 12
3.3.3 Coreg (Carvedilol) 13
3.3.4 Altace (Ramipril) 14
3.3.5 Atacand (Candesartan) 15
3.3.6 Bidil (Isosorbide Dinitrate and Hydralazine Hydrochloride) 16
3.4 Key Takeaway 17
4 Acute Heart Failure: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18
4.3 Acute Heart Failure Therapeutics-Promising Drugs under Clinical Development 19
4.4 Drugs under Clinical Development 20
4.4.1 Tekturna/Rasilez 20
4.4.2 Lixivaptan 20
4.4.3 Relaxin 21
4.4.4 Cinaciguat 22
4.5 Acute Heart Failure Therapeutics Market-Clinical Pipeline by Mechanism of Action 22
4.6 Acute Heart Failure Pipeline-Pipeline by Clinical Phases of Development 23
4.6.1 Acute Heart Failure Therapeutics-Phase III Clinical Pipeline 23
4.6.2 Acute Heart Failure Therapeutics-Phase II Clinical Pipeline 24
4.6.3 Acute Heart Failure Therapeutics-Phase I Clinical Pipeline 24
4.6.4 Acute Heart Failure Therapeutics-Preclinical Pipeline 24
4.7 Discontinued/Suspended Drugs for Acute Heart Failure 24
4.8 Key Takeaway 25
5 Acute Heart Failure Market: Implications for Future Market Competition 26
6 Acute Heart Failure Market: Future Players in the Acute Heart Failure Market 27
6.1 Introduction 27
6.2 Novartis AG 27
6.2.1 Overview 27
6.2.2 Business Description 28
6.2.3 Cardiovascular Portfolio 29
6.2.4 Acute Heart Failure Product Portfolio 29
6.3 Biogen Idec. 31
6.3.1 Overview 31
6.3.2 Business Description 31
6.3.3 Cardiovascular Portfolio 32
6.3.4 Acute Heart Failure Product Portfolio 32
6.4 Bayer AG 32
6.4.1 Overview 32
6.4.2 Business Description 33
6.4.3 Cardiovascular Portfolio 34
6.4.4 Acute Heart Failure product portfolio 34
7 Acute Heart Failure Market: Appendix 35
7.1 Definitions 35
7.2 Abbreviations 35
7.3 Research Methodology 36
7.3.1 Coverage 36
7.3.2 Secondary Research 37
7.3.3 Forecasting 37
7.3.4 Primary Research 40
7.3.5 Expert Panels 40
7.4 Contact Us 40
7.5 Disclaimer 40
7.6 Sources 41

List of Tables
1.1 List of Tables
Table 1: Global   AHF Market Revenues ($m), 2001-2009 6
Table 2: Global  AHF Market Revenues ($m), 2009-2016 7
Table 3: Major Marketed Product in the Acute Heart Failure Market, 2010 17
Table 4: Acute Heart Failure Therapeutics-Promising Drugs Under Clinical Development, 2010 19
Table 5: Acute Heart Failure Therapeutics-Phase III Clinical Pipeline, 2010 23
Table 6: Acute Heart Failure Therapeutics-Phase II Clinical Pipeline, 2010 24
Table 7: Acute Heart Failure Therapeutics-Phase I Clinical Pipeline, 2010 24
Table 8: Acute Heart Failure Therapeutics-Preclinical Pipeline, 2010 24
Table 9: List of Discontinued Drugs for Acute Heart Failure, 2010 24
Table 10: Novartis AG-Cardiovascular and Acute Heart Failure Pipeline, 2010 29
Table 11: Biogen Idec.-Cardiovascular and Acute Heart Failure Pipeline, 2010 32
Table 12: Bayer AG-Cardiovascular and Acute Heart Failure Pipeline, 2010 34

List of Figures
1.2 List of Figures
Figure 1: Global Acute Heart Failure Market Revenue ($m), 2001-2009 6
Figure 2: Global AHF Market Forecast ($m), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the AHF Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Acute Heart Failure, 2010 11
Figure 5: Technology Trends Analytic Framework of the Acute Heart Failure Pipeline, 2010 18
Figure 6: Technology Trends Analytic Framework  of Acute Heart Failure Pipeline,  Description, 2010 19
Figure 7: Acute Heart Failure Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Acute Heart Failure Pipeline by Phase of Clinical Development, 2010 23
Figure 9: Implications for Future Market Competition in the Acute Heart Failure Market, 2010 26
Figure 10: Acute Heart Failure Therapeutics Market-Clinical Pipeline by Company, 2010 27
Figure 11: GlobalData Methodology 36
Figure 12: GlobalData Market Forecasting Model 39